Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719966 · ClinicalTrials.gov registry record
Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 109
- Enrollment target
NCT00719966: Completed study, sponsored by Mayo Clinic.
NCT00719966 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 109 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00719966 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
Study Summary
RATIONALE: Aromatase inhibitor therapy is used in treating postmenopausal women who have hormone-dependent breast cancer. It is not yet known what effect aromatase inhibitor therapy has on blood vessel function. PURPOSE: This clinical trial is studying the effect of aromatase inhibitor therapy on blood vessel function in postmenopausal women with breast cancer.
Interventions
- DRUG letrozole
- DRUG anastrozole
- DRUG exemestane
- PROCEDURE assessment of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2008-09-18 |
| Est. Completion | 2020-01-24 |
What the finished NCT00719966 record still lists
NCT00719966 is an observational study that tracks outcomes without assigning an intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 4 interventions - of which letrozole is the first listed.
NCT00719966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00719966 about?
NCT00719966 is a clinical study titled "Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer". RATIONALE: Aromatase inhibitor therapy is used in treating postmenopausal women who have hormone-dependent breast cancer. It is not yet known what effect aromatase inhibitor therapy has on blood vessel function. PURPOSE: This clinical trial is studying the effect of aromatase inhibitor therapy on b...
What is the current status of trial NCT00719966?
This trial is currently completed. The enrollment target is 109 participants. The study started on 2008-09-18. Estimated completion is 2020-01-24.
What interventions are being tested in trial NCT00719966?
The interventions under investigation include: letrozole (DRUG), anastrozole (DRUG), exemestane (DRUG), assessment of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00719966?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI